Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) stock fell -0.72% on Monday to $13.71 against a previous-day closing price of $13.81. With 0.71 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.23 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.90 whereas the lowest price it dropped to was $13.53. The 52-week range on CPRX shows that it touched its highest point at $22.11 and its lowest point at $11.09 during that stretch. It currently has a 1-year price target of $23.30. Beta for the stock currently stands at 1.09.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CPRX was up-trending over the past week, with a rise of 8.55%, but this was up by 7.11% over a month. Three-month performance dropped to -4.92% while six-month performance rose 10.12%. The stock lost -10.39% in the past year, while it has lost -26.29% so far this year. A look at the trailing 12-month EPS for CPRX yields 0.53 with Next year EPS estimates of 1.28. For the next quarter, that number is 0.28. This implies an EPS growth rate of -21.07% for this year and 115.88% for next year.
Float and Shares Shorts:
At present, 105.26 million CPRX shares are outstanding with a float of 91.65 million shares on hand for trading. On Oct 30, 2023, short shares totaled 6.42 million, which was 6.02% higher than short shares on Sep 28, 2023. In addition to Mr. Patrick J. McEnany as the firm’s Co-Founder, Chairman, President & CEO, Ms. Alicia Grande C.M.A., CPA serves as its Chief Accounting Officer, VP, Treasurer & CFO.
Through their ownership of 84.22% of CPRX’s outstanding shares, institutional investors have majority control over the company. With a 6.35% stake in CPRX, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 6,763,281 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 4.15% of CPRX stock, is the second-largest Mutual Fund holder. It holds 4,423,788 shares valued at 54.9 million. Vanguard Total Stock Market ETF holds 2.94% of the stake in CPRX, owning 3,135,615 shares worth 38.91 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CPRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CPRX analysts setting a high price target of $27.00 and a low target of $15.50, the average target price over the next 12 months is $23.30. Based on these targets, CPRX could surge 96.94% to reach the target high and rise by 13.06% to reach the target low. Reaching the average price target will result in a growth of 69.95% from current levels.
Summary of Insider Activity:
Insiders traded CPRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 42 while that of sell transactions has risen to 32 over the past year. The total number of shares bought during that period was 1,265,668 while 839,003 shares were sold.